Toxicity of Doxorubicin (Dox) to different experimental organ systems

Area of Science:

• Oncology
• Pharmacology
• Toxicology

Background:

• Doxorubicin (Dox) is a cornerstone chemotherapy agent for treating various hematologic and solid tumors.
• Despite its efficacy, Dox is associated with significant multi-organ toxicities, limiting its clinical application.
• Evaluating Dox-induced toxicity is crucial for preclinical and clinical research.

Purpose of the Study:

• To review the multi-organ toxicities associated with Doxorubicin treatment.
• To elucidate the most probable underlying mechanisms of Dox-induced organ damage.
• To specifically investigate the role of oxidative stress in Dox-induced cardiotoxicity.

Main Methods:

• Literature review of preclinical and clinical studies on Doxorubicin toxicity.
• Analysis of proposed mechanisms of Dox-induced organ damage.
• Focus on evaluating the evidence for oxidative stress as a key pathogenic factor.

Main Results:

• Doxorubicin exhibits toxicity across multiple organ systems.
• Several mechanisms contribute to Dox-induced toxicity, including DNA damage, topoisomerase II inhibition, and iron-mediated free radical production.
• Oxidative stress is identified as a highly probable mechanism, particularly for the cardiotoxic effects of Doxorubicin.

Conclusions:

• Doxorubicin's clinical utility is significantly impacted by its dose-dependent multi-organ toxicities.
• Understanding the mechanisms of toxicity, especially oxidative stress, is essential for developing strategies to mitigate Dox-induced adverse effects.
• Further research is warranted to confirm and target the role of oxidative stress in preventing Doxorubicin cardiotoxicity.